The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination
Launched by MUHAMMAD ILYAS · May 2, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how effective a combination of two medications, pregabalin and etoricoxib, is in reducing pain and improving daily activities for people suffering from chronic low back pain that comes from nerve issues. The researchers believe that taking both medications together will work better than taking just etoricoxib alone. The study will involve 140 participants aged 20 to 65, who have been experiencing chronic low back pain for at least six months. To participate, individuals should not have had any prior back surgeries or taken certain medications that could interfere with the study.
Participants in the study will be divided into two groups. One group will take etoricoxib alone for the first four weeks, while the other group will take it along with pregabalin during the second phase of the trial. Throughout the study, participants will have their pain levels measured and will answer questions about how their back pain affects their daily life. It’s important to note that the trial is not yet recruiting participants, so interested individuals will need to wait for further announcements about enrollment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants within age 20-65 years
- • Both male and non-pregnant non-lactating female patients will be included in the study
- • Patients experiencing CLBP symptoms from last 6 months
- Exclusion Criteria:
- • • Patients with the history of antidepressant, opioid, and benzodiazepine medications
- • Patients with the history of CYP1A2 inhibitors usage
- • Patients already taking pregabalin
- • Patients with the history of suicidal ideation, severe depression, anxiety disorder psychosis, and cognitive impairment
About Muhammad Ilyas
Muhammad Ilyas is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative clinical studies. With a focus on ethical practices and regulatory compliance, Ilyas leads a team of experienced professionals in the design, implementation, and oversight of clinical trials across various therapeutic areas. His leadership ensures that trials are conducted with the utmost integrity and scientific rigor, fostering collaboration with healthcare providers, research institutions, and regulatory agencies to facilitate the development of safe and effective therapies. Through his expertise and vision, Muhammad Ilyas strives to contribute significantly to the advancement of healthcare and the well-being of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported